Peptide pulse · May 2026: orforglipron approved, oral Wegovy live, RFK reclassification, and the 503B endgame

The last 60 days reset the peptide map more than any 60-day window since semaglutide's first label expansion. Five things landed in roughly the order they shipped: oral Wegovy approved (late December 2025), TRIUMPH-4 retatrutide readout (December 2025), Novo filed the CagriSema NDA (December 2025), RFK announced the FDA Category 2 peptide reclassification (February 2026), Foundayo (orforglipron) approved early via the National Priority Voucher program (April 1), survodutide phase 3 obesity readout (April 28), and the FDA proposed excluding tirzepatide from the 503B bulks list (April 30) with a comment period through June 29.

This is the May 2026 snapshot. What actually changed in the public record, what each shift means for routing decisions, and where the gaps still are. Sources at the bottom.

Stale content note: our horizon piece on 6 peptides 2026-2028 framed orforglipron, TRIUMPH-4, and survodutide phase 3 as future events. By the time it published, all three had already moved · we now correct in this piece. The horizon piece still holds for MariTide, the MASH indication for survodutide, and the longer-tail readouts on retatrutide TRIUMPH-3 (which is the actual cardiovascular outcomes trial, not TRIUMPH-4 as we originally wrote).

1. Foundayo (orforglipron) approved · April 1, 2026

Lilly's oral small-molecule GLP-1 received FDA approval on April 1, 2026 under the new National Priority Voucher program · 50 days after filing, 294 days ahead of its January 20, 2027 PDUFA date. This is the fastest approval of a new molecular entity since 2002. Brand: Foundayo.

Efficacy: ATTAIN-1 (72 weeks, 3,127 adults with obesity, no diabetes) · 12.4% mean weight reduction at the 36mg high dose, 0.9% on placebo. ATTAIN-2 (T2D + obesity) · 10.5% at the high dose at 72 weeks.

Mechanism: not a peptide despite the name · orforglipron is an oral small-molecule GLP-1 receptor agonist. No injection. No cold chain. No food or water restriction, unlike Rybelsus (oral semaglutide) which requires fasting. T2D submission planned for later in 2026.

Routing impact:

• The supply story for the GLP-1 class fundamentally shifts. Small molecule manufacturing scales differently from peptide synthesis · multiple contract manufacturers, shorter lead times, geographically distributed capacity. The bottleneck that defined the 2023-2025 GLP-1 era unwinds over the next 18 months.
• Efficacy is not the headline · 12.4% lands closer to semaglutide than tirzepatide. If maximum efficacy is the goal, tirzepatide and the next-generation incretins (CagriSema, retatrutide) remain the answer.
• Watch the first 90 days of commercial pricing. Lilly listed Foundayo at a list price intended to undercut current injectable pricing. Generics-track economics over 24-36 months would re-floor the entire class.

Panya rating posture: WATCH for first 90 days of supply data, then routable for cohorts where (a) injection adherence is the limiting factor or (b) cost is the routing variable. Not a routable answer for cohorts targeting >20% reduction.

2. Oral Wegovy (semaglutide 25mg pill) · approved late December 2025, available January 2026

Novo's oral semaglutide line crossed the obesity indication in late December 2025. The 25mg pill became commercially available in January 2026 at a list price of $149/month per the manufacturer.

Efficacy (OASIS 4 trial): -13.6% body weight change at 25mg vs -2.4% on placebo at the obesity-cohort endpoint. The 50mg dose data was favorable in trials but is not yet in clinical use.

Routing impact:

• Two oral GLP-1 options now exist. Foundayo (small molecule, no food/water restriction, 12.4%) vs oral Wegovy (peptide, fasting + small water, 13.6%). Side-by-side, the convenience advantage tilts to Foundayo; the efficacy is roughly comparable.
• Cohort split: orals are the right fit for needle-averse readers, travelers (no cold chain, no syringes), and patients on the BMI-27-30 band where injectable cost-justification is harder.
• Oral does NOT solve the GLP-1 class side-effect profile · GI side effects track similar to injectable doses on a per-dose basis.

Panya rating posture: routable for the cohorts above; existing tirzepatide / injectable-semaglutide routing unchanged for high-BMI cohorts.

3. RFK peptide reclassification · 14 substances off Category 2 effective April 23, 2026

On February 27, 2026, HHS Secretary Kennedy publicly announced the FDA was moving roughly 14 peptide substances off the Category 2 (prohibited from compounding) list. The substances came off Category 2 effective April 23, 2026. The Pharmacy Compounding Advisory Committee (PCAC) reviews them on July 23-24, 2026 to evaluate inclusion on the 503A bulks list (formal compounding eligibility).

In scope: BPC-157 (acetate + free base), TB-500 (Thymosin Beta-4), Thymosin Alpha-1, KPV, MOTs-C, CJC-1295, Ipamorelin. (Not all 14 have been publicly enumerated; this is the well-confirmed subset.)

What this does NOT mean: a Category 2 → off-Category-2 move does not automatically authorize compounding. Until PCAC reviews and FDA acts on a 503A bulks list addition, no licensed 503A or 503B pharmacy in the United States can legally produce these peptides. The reclassification opens the door; the rulemaking that actually authorizes compounded production is downstream.

Routing impact:

• Editorial: any vendor scorecard or guide that says "BPC-157 is FDA Category 2 prohibited" needs updating to reflect the post-April-23 status (off Category 2, pending PCAC review).
• Routing: no change yet. Compounded BPC-157 / TB-500 / etc. is not licensed today and will not be until at least August 2026 if PCAC + FDA both act favorably.
• The legitimate-supply story may improve in late 2026 if rulemaking lands. Routing recommendations stay on hold until then.

Panya rating posture: unchanged. Updates to Category 2 framing on existing vendor pages + posts to land in this sprint.

4. FDA proposes excluding tirzepatide from 503B bulks list · April 30, 2026

On April 30, 2026, the FDA formally proposed excluding tirzepatide from the 503B bulks list, citing no demonstrated clinical need for outsourcing facilities to compound it from bulk substances. Public comment open through June 29, 2026, with the agency expected to issue a final decision after.

Context: Semaglutide and tirzepatide both came off the FDA shortage list in late 2024 / early 2025. 503A pharmacies lost enforcement discretion February 11, 2025; 503B outsourcers lost it March 19, 2025. The April 30 proposal is the formal codification · once finalized, "essentially a copy" compounding of tirzepatide is permanently impermissible at scale.

What is still permissible:

• 503A compounding for individualized medical necessity (documented allergy to a specific inactive ingredient, clinically justified non-standard concentration, etc.).
• This is a narrow lane. It is not the mass-compounded Hims-style telehealth model.

Routing impact:

• Telehealth firms that built their business around compounded tirzepatide / semaglutide (Hims, Ro, smaller operators) lose their primary supply channel. Some pivot to brand prescriptions; some pivot to oral options; some shrink.
• US patients who relied on compounded tirzepatide for cost reasons face a forced migration to brand pricing or oral alternatives.
• The grey-market and research-chemical channels likely see a temporary demand spike from price-sensitive cohorts unwilling to migrate to brand.

Panya rating posture: any vendor scorecard that scored a 503B-channel compounder as routable needs the verdict reviewed. The legal-channel routability of mass compounded GLP-1 is gone after the final rule lands. Brand-pharmacy routing rises on the rubric. Survey + update queued for next vendor catalog round.

5. TRIUMPH-4 readout (December 2025) · 28.7% weight loss · obesity + knee osteoarthritis

Lilly's TRIUMPH-4 trial reported in December 2025: 28.7% mean body weight reduction at 12mg in adults with obesity and knee osteoarthritis at 68 weeks. WOMAC pain scores reduced by up to 4.5 points (75.8%). Systolic BP reduction of 14.0 mmHg at 12mg. Roughly 1 in 8 patients ended the trial completely free from knee pain.

Note vs our earlier framing: we previously implied TRIUMPH-4 was the cardiovascular outcomes trial. That is TRIUMPH-3, which enrolls participants with obesity and established cardiovascular disease and reads out 2027 at the earliest. TRIUMPH-4 was the obesity + knee OA cohort, and it landed.

Routing impact: the 28.7% headline puts retatrutide above tirzepatide on weight reduction by roughly 6 percentage points at the matching dose. The OA pain reduction reframes retatrutide's downstream label scope · this is now plausibly a dual-indication drug (obesity + chronic OA pain), not an obesity-only one.

Panya rating posture: still HOLD on routing recommendations until FDA decision (filing late 2026, decision likely late 2027) plus 90 days of commercial supply. Waiting list will be long; routing posture becomes meaningful at the launch-supply stage.

6. Survodutide phase 3 obesity readout · April 28, 2026

Boehringer Ingelheim and Zealand reported the survodutide phase 3 obesity readout on April 28, 2026: 16.6% mean weight loss in adults with obesity or overweight. The headline placed survodutide closer to Wegovy (15.0% at the matching endpoint) than to tirzepatide (22.5% at SURMOUNT-1). SYNCHRONIZE-MASLD readout still expected later in 2026.

Routing impact:

• As a pure obesity routing question, survodutide does not rewrite the map · it is the second-best dual agonist on weight after retatrutide.
• The MASH indication remains the more interesting routing case. LIVERAGE + LIVERAGE-Cirrhosis (phase 3 MASH) and SYNCHRONIZE-MASLD (obesity + MASH) readouts in late 2026 will determine whether survodutide becomes the first injectable peptide approved specifically for steatotic liver disease.
• FDA Breakthrough Therapy designation already in place for non-cirrhotic MASH with stage 2 or 3 fibrosis · this fast-tracks the regulatory path.

Panya rating posture: HOLD on obesity routing. MASH-specific routing recommendation deferred until LIVERAGE phase 3 reads out.

7. CagriSema NDA filed (December 2025) · REDEFINE-2 confirmed at 15.7%

Novo filed the CagriSema NDA with the FDA in December 2025 on the strength of REDEFINE-1 and REDEFINE-2. REDEFINE-2 (T2D + obesity, 1,206 randomized, 68 weeks) confirmed 15.7% weight loss · close to but below tirzepatide on the same indication. REIMAGINE-2 (T2D head-to-head) showed 14.2% weight loss with HbA1c -1.91 percentage points · the diabetes-control story is real.

Routing impact:

• CagriSema is a refinement, not a generational leap. Below tirzepatide on weight, comparable on glycemic control.
• The amylin-mediated lean-mass-preservation hypothesis from earlier sprint analyses is still not definitively answered by REDEFINE phase 3 endpoints (which are weight + HbA1c, not body composition).
• FDA review window: 2026 to 2027.

Panya rating posture: HOLD pending approval. Watch for body-composition substudies that may make the lean-mass case.

8. Counterfeit + supply-chain warnings · April 2026

A 60-day window of supply-side enforcement events worth tracking together:

• April 6, 2026: A Utah physician was indicted for selling misbranded peptides sourced from China to over 200 patients. Compounds included tirzepatide, semaglutide, retatrutide, cagrilintide, and NAD+ · obtained through a middleman.
• Cincinnati customs seizure: 5,000 unapproved peptide vials intercepted in a single border action.
• Texas testing-lab data: roughly 33% of consumer peptide samples tested fail at least one quality benchmark · identity, purity, or stated dose.
• FDA warning letters: ongoing warning-letter cadence to research-peptide vendors (Excel Peptides, Swiss Chems, Summit Research, Prime Peptides, USA Peptides among the named).
• FDA green-list import alert (66-80): targets GLP-1 active pharmaceutical ingredients with quality concerns at the import gate.

Routing impact:

• The grey-market premium-quality story is structurally weaker than it was 60 days ago. Even readers who routed to research-chem for cost reasons are now operating in a denser enforcement environment.
• The "Janoshik COA + reputable vendor" routing pattern still applies but now with an explicit caveat: a clean COA does not protect against import seizure or post-shipment enforcement.
• Editorial: any guide that says "research-chem is fine if you check the COA" needs the supply-chain caveat appended.

Panya rating posture: unchanged on the rubric, but the verdict line on grey-market vendors should weight the post-April-2026 enforcement context. Survey + update queued.

Regional snapshots

United Kingdom: Tirzepatide enters the 2026/27 GP contract via QOF indicators effective April 1, 2026. Cohort 2 (BMI 35-39.9) starts June 2026. Cohort 3 (BMI ≥40 + 3 conditions) April 2027. NHS prescription charges apply unless exempt. NICE TA1026 + MHRA license both require structured wraparound care.

Singapore: HSA approved Mounjaro KwikPen for adult weight management in June 2025. Wegovy adolescent indication added 2025; CV-risk-reduction indication added for adults with established CV disease and obesity/overweight. HSA actively assessing the suicidal-thoughts/self-harm signal across the GLP-1 RA class.

Thailand: Wegovy 1.7mg + 2.4mg pens available. Counterfeit raids ongoing; Thai FDA recommends prescription channels via licensed clinics or pharmacies. Customs continues to inspect/seize unmarked biological vials at the border.

What we are watching for the next 60 days

1. PCAC meeting July 23-24, 2026: BPC-157, KPV, TB-500, MOTs-C, CJC-1295, Ipamorelin, Thymosin Alpha-1 reviewed for 503A bulks list inclusion. Outcome determines whether compounded peptide therapy becomes legally accessible by Q4 2026. 2. Tirzepatide 503B exclusion final rule: comment period closes June 29; final rule likely Q3 2026. 3. SYNCHRONIZE-MASLD readout (survodutide obesity + MASH): expected later in 2026. 4. CagriSema FDA decision: review ongoing, decision window 2026-2027. 5. First 90 days of Foundayo commercial supply: will it deliver on the small-molecule scale-up thesis? 6. Telehealth pivot stories (Hims, Ro, etc.) post-503B-exclusion: which model survives the final rule?

We will publish per-event updates as each lands. The cycle of "phase 3 readout → FDA decision → commercial supply → routing change" is now compressed to weeks for the headline events; this post is our discipline for staying in front of it.

For the live retatrutide deep-dive, see /blog/retatrutide-phase-3-update-2026. For the original horizon framing (with the corrections noted at the top of this piece), see /blog/fda-horizon-six-peptides-2026-2028. For the methodology behind every routing call, see /blog/11-signals-vendor-rubric.

Sources

• Lilly investor release on Foundayo approval and the National Priority Voucher program (investor.lilly.com)
• FDA press announcement on first NME under National Priority Voucher (fda.gov)
• Lilly TRIUMPH-4 readout (knee OA + obesity, 28.7%) (investor.lilly.com)
• Boehringer/Zealand survodutide phase 3 obesity readout (16.6%, April 28, 2026) (globenewswire.com)
• FDA proposal to exclude tirzepatide from 503B bulks list (April 30, 2026) (fda.gov) and Foley & Lardner analysis (foley.com)
• RFK Category 2 reclassification announcement and PCAC July 23-24 meeting docket (fda.gov, fiercepharma.com)
• Novo CagriSema NDA filing announcement and REDEFINE-2 / REIMAGINE-2 readouts (globenewswire.com)
• Oral Wegovy 25mg approval and OASIS 4 (endocrinologyadvisor.com)
• Utah physician indictment + Cincinnati customs seizure (Partnership for Safe Medicines, April 6, 2026) (safemedicines.org)
• NHS Tirzepatide 2026/27 GP contract integration (england.nhs.uk)
• HSA Singapore Mounjaro KwikPen approval and Wegovy adolescent indication (cliffordclinic.com)
• Thailand customs / Thai FDA peptide guidance (thailandpeptide.com)